TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01952561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine ring
Study: NCT02114320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-BD
Description: EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-BD
Description: EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
Study: NCT00203099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate, N-Acetylcysteine
Description: Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
Study: NCT04721886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonsgraphy
Description: Undergo ultrasonography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microcpheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast - Enhanced Ultrasound
Description: Undergo CEUS
Study: NCT03566134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-8010 Placebo
Description: Participants receive placebo to match DA-8010 orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-8010 Placebo
Description: Participants receive placebo to match DA-8010 orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg
Description: Participants receive DA-8010 2.5mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg
Description: Participants receive DA-8010 5mg orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin 5mg
Description: Participants receive solifenacin 5 mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solifenacin succinate placebo
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.
Study: NCT04178668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral mucosa and saliva samples
Description: one oral mucosa sample and one saliva sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral mucosa and saliva samples
Description: one oral mucosa sample and one saliva sample
Study: NCT04193995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
Study: NCT02832115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Nitroglycerine
Description: Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Lidocaine
Description: Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Lidocaine
Description: Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
Study: NCT02919995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: RPL554 suspension administered using a nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: RPL554 suspension administered using a nebuliser

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution administered using a nebuliser
Study: NCT01887457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VFEND
Description: voriconazole will be administered in iv form
Study: NCT04491318

Intervention type: OTHER
Intervention: Observational
Description: Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
Study: NCT03319147

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: 4g of essential amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4g of maltdextrin
Study: NCT00594841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation of AC joint dislocation
Description: Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~* Anatomic reduction of the AC joint~* Definitive fixation with a hook plate and screws

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non operative treatment of AC joint dislocation (sling)
Description: Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
Study: NCT03818321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1 g tablet
Description: Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
Study: NCT02196636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, administered orally with approximately 240 mL of buffer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, administered orally with approximately 240 mL of buffer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6806127
Description: Administered orally with approximately 240 mL of buffer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6806127
Description: Administered orally with approximately 240 mL of buffer
Study: NCT03155906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care delivery
Description: Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health care delivery
Description: Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
Study: NCT05827172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.

Intervention type: OTHER
Group type: OTHER
Intervention: medical therapy
Description: The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
Study: NCT01035125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program
Description: Participants will receive a one week inpatient self-management program
Study: NCT01249261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Risedronate
Description: placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
Study: NCT03324087

Intervention type: DIAGNOSTIC_TEST
Intervention: HRQoL
Description: use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
Study: NCT03758040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slips on Turns
Description: Subjects will be administered a slip at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slips on Slopes
Description: Slips will be administered at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the CAREN system treadmill.
Study: NCT01441076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
Study: NCT02955667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: invivo microscopy group
Description: patients receive invivo micro-colposcopy examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: normal group
Description: patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
Study: NCT02559141

Intervention type: DRUG
Group type: OTHER
Intervention: Dobutamine
Description: If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
Study: NCT01099462

Intervention type: DRUG
Intervention: Ibuprofen
Description: Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
Study: NCT02947789

Intervention type: PROCEDURE
Intervention: Emergency surgery
Description: Patients undergoing emergency surgery
Study: NCT02892448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
Study: NCT01153932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matched placebo
Description: Subcutaneous injection
Study: NCT02058303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Forearm block
Description: 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine supraclavicular block
Description: 20-30mL 0.5% bupivacaine
Study: NCT05741671

Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.

Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.

Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.

Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.

Intervention type: OTHER
Intervention: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
Study: NCT00089362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvespimycin hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02094690

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therabite
Description: 10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperboloid
Description: 5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperboloid
Description: 5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
Study: NCT02866279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel Contraceptive Implant
Description: Women will be randomized to the TIMING of implant placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel Contraceptive Implant
Description: Women will be randomized to the TIMING of implant placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel Contraceptive Implant
Description: Women will be randomized to the TIMING of implant placement
Study: NCT00553709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine
Description: Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
Study: NCT04501185

Intervention type: DEVICE
Intervention: total hip arthroplasty
Description: The indication for total hip arthroplasty is mainly osteoarthritis.

Intervention type: DEVICE
Intervention: total hip arthroplasty
Description: The indication for total hip arthroplasty is mainly osteoarthritis.
Study: NCT04194528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen 5/325 mg
Description: The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus digital medicine program
Description: The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.